Prior Trend of Biotechnology Stocks:VVUS

New York, NY -- (SBWIRE) -- 12/20/2012 -- VIVUS Inc. (NASDAQ:VVUS) is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic drugs for underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes, and men's sexual health.

VIVUS, Inc.(NASDAQ:VVUS) was among the finest moving Biotech stocks on Thursday, as its shares pumped up 2.05% after the news that the firm declared Express Scripts, among the country’s biggest Pharmacy Benefit Managers (PBMs), has included Qsymia™ to its national pharmacy formularies, allowing for coverage where accessible by benefit design of the first new FDA-accepted medication commercially accessible in the US in over a decade for the cure of chronic weight management.

Shares of VVUS climbed 3.81% to $13.64 in the previous trading session. The company showed strong growth in weekly prescriptions for its Qsymia pill, the latest fat-fighter on the U.S. market. Healthcare research firm Symphony Health Solutions reported a 44% jump in Qsymia prescriptions for the week ended November 12, while other industry body, IMS Health, pointed to a 15% rise in prescriptions during the same period.

How Should Investors Trade VVUS After The Recent Volatile Moves? Find Out Here

DISCLAIMER
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.biz